ArticlePloS one2021

Evaluation of combination protocols of the chemotherapeutic agent FX-9 with azacitidine, dichloroacetic acid, doxorubicin or carboplatin on prostate carcinoma cell lines.

Franziska Weiner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.